Arterial wall dosimetry for non-hodgkin lymphoma patients treated with radioimmunotherapy

Robert Hobbs, Sébastien Baechler, Richard L. Wahl, Bin He, Hong Song, Caroline E. Esaias, Eric Frey, Heather Jacene, George Sgouros

Research output: Contribution to journalArticle

Abstract

Tumors in non-Hodgkin lymphoma (NHL) patients are often proximal to the major blood vessels in the abdomen or neck. In external-beam radiotherapy, these tumors present a challenge because imaging resolution prevents the beam from being targeted to the tumor lesion without also irradiating the artery wall. This problem has led to potentially life-threatening delayed toxicity. Because radioimmunotherapy has resulted in long-term survival of NHL patients, we investigated whether the absorbed dose (AD) to the artery wall in radioimmunotherapy of NHL is of potential concern for delayed toxicity. SPECT resolution is not sufficient to enable dosimetric analysis of anatomic features of the thickness of the aortic wall. Therefore, we present a model of aortic wall toxicity based on data from 4 patients treated with 131I- tositumomab. Methods: Four NHL patients with periaortic tumors were administered pretherapeutic 131I-tositumomab. Abdominal SPECT and whole-body planar images were obtained at 48, 72, and 144 h after tracer administration. Blood-pool activity concentrations were obtained from regions of interest drawn on the heart on the planar images. Tumor and blood activity concentrations, scaled to therapeutic administered activities - both standard and myeloablative - were input into a geometry and tracking model (GEANT, version 4) of the aorta. The simulated energy deposited in the arterial walls was collected and fitted, and the AD and biologic effective dose values to the aortic wall and tumors were obtained for standard therapeutic and hypothetical myeloablative administered activities. Results: Arterial wall ADs from standard therapy were lower (0.6-3.7 Gy) than those typical from external-beam therapy, as were the tumor ADs (1.4-10.5 Gy). The ratios of tumor AD to arterial wall AD were greater for radioimmunotherapy by a factor of 1.9-4.0. For myeloablative therapy, artery wall ADs were in general less than those typical for external-beam therapy (9.4-11.4 Gy for 3 of 4 patients) but comparable for 1 patient (32.6 Gy). Conclusion: Blood vessel radiation dose can be estimated using the software package 3D-RD combined with GEANT modeling. The dosimetry analysis suggested that arterial wall toxicity is highly unlikely in standard dose radioimmunotherapy but should be considered a potential concern and limiting factor in myeloablative therapy.

Original languageEnglish (US)
Pages (from-to)368-375
Number of pages8
JournalJournal of Nuclear Medicine
Volume51
Issue number3
DOIs
StatePublished - Mar 2010

Fingerprint

Radioimmunotherapy
Non-Hodgkin's Lymphoma
Neoplasms
Arteries
Single-Photon Emission-Computed Tomography
Therapeutics
Blood Vessels
Body Image
Abdomen
Aorta
Neck
Radiotherapy
Software
Radiation
Survival

Keywords

  • Lymphoma
  • Monte Carlo
  • Oncology
  • Radiobiology/dosimetry
  • Radioimmunotherapy
  • Radionuclide therapy
  • SPECT/CT
  • Toxicity

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Arterial wall dosimetry for non-hodgkin lymphoma patients treated with radioimmunotherapy. / Hobbs, Robert; Baechler, Sébastien; Wahl, Richard L.; He, Bin; Song, Hong; Esaias, Caroline E.; Frey, Eric; Jacene, Heather; Sgouros, George.

In: Journal of Nuclear Medicine, Vol. 51, No. 3, 03.2010, p. 368-375.

Research output: Contribution to journalArticle

Hobbs, Robert ; Baechler, Sébastien ; Wahl, Richard L. ; He, Bin ; Song, Hong ; Esaias, Caroline E. ; Frey, Eric ; Jacene, Heather ; Sgouros, George. / Arterial wall dosimetry for non-hodgkin lymphoma patients treated with radioimmunotherapy. In: Journal of Nuclear Medicine. 2010 ; Vol. 51, No. 3. pp. 368-375.
@article{feebef5bd59042a780f240af111f480a,
title = "Arterial wall dosimetry for non-hodgkin lymphoma patients treated with radioimmunotherapy",
abstract = "Tumors in non-Hodgkin lymphoma (NHL) patients are often proximal to the major blood vessels in the abdomen or neck. In external-beam radiotherapy, these tumors present a challenge because imaging resolution prevents the beam from being targeted to the tumor lesion without also irradiating the artery wall. This problem has led to potentially life-threatening delayed toxicity. Because radioimmunotherapy has resulted in long-term survival of NHL patients, we investigated whether the absorbed dose (AD) to the artery wall in radioimmunotherapy of NHL is of potential concern for delayed toxicity. SPECT resolution is not sufficient to enable dosimetric analysis of anatomic features of the thickness of the aortic wall. Therefore, we present a model of aortic wall toxicity based on data from 4 patients treated with 131I- tositumomab. Methods: Four NHL patients with periaortic tumors were administered pretherapeutic 131I-tositumomab. Abdominal SPECT and whole-body planar images were obtained at 48, 72, and 144 h after tracer administration. Blood-pool activity concentrations were obtained from regions of interest drawn on the heart on the planar images. Tumor and blood activity concentrations, scaled to therapeutic administered activities - both standard and myeloablative - were input into a geometry and tracking model (GEANT, version 4) of the aorta. The simulated energy deposited in the arterial walls was collected and fitted, and the AD and biologic effective dose values to the aortic wall and tumors were obtained for standard therapeutic and hypothetical myeloablative administered activities. Results: Arterial wall ADs from standard therapy were lower (0.6-3.7 Gy) than those typical from external-beam therapy, as were the tumor ADs (1.4-10.5 Gy). The ratios of tumor AD to arterial wall AD were greater for radioimmunotherapy by a factor of 1.9-4.0. For myeloablative therapy, artery wall ADs were in general less than those typical for external-beam therapy (9.4-11.4 Gy for 3 of 4 patients) but comparable for 1 patient (32.6 Gy). Conclusion: Blood vessel radiation dose can be estimated using the software package 3D-RD combined with GEANT modeling. The dosimetry analysis suggested that arterial wall toxicity is highly unlikely in standard dose radioimmunotherapy but should be considered a potential concern and limiting factor in myeloablative therapy.",
keywords = "Lymphoma, Monte Carlo, Oncology, Radiobiology/dosimetry, Radioimmunotherapy, Radionuclide therapy, SPECT/CT, Toxicity",
author = "Robert Hobbs and S{\'e}bastien Baechler and Wahl, {Richard L.} and Bin He and Hong Song and Esaias, {Caroline E.} and Eric Frey and Heather Jacene and George Sgouros",
year = "2010",
month = "3",
doi = "10.2967/jnumed.109.069575",
language = "English (US)",
volume = "51",
pages = "368--375",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "3",

}

TY - JOUR

T1 - Arterial wall dosimetry for non-hodgkin lymphoma patients treated with radioimmunotherapy

AU - Hobbs, Robert

AU - Baechler, Sébastien

AU - Wahl, Richard L.

AU - He, Bin

AU - Song, Hong

AU - Esaias, Caroline E.

AU - Frey, Eric

AU - Jacene, Heather

AU - Sgouros, George

PY - 2010/3

Y1 - 2010/3

N2 - Tumors in non-Hodgkin lymphoma (NHL) patients are often proximal to the major blood vessels in the abdomen or neck. In external-beam radiotherapy, these tumors present a challenge because imaging resolution prevents the beam from being targeted to the tumor lesion without also irradiating the artery wall. This problem has led to potentially life-threatening delayed toxicity. Because radioimmunotherapy has resulted in long-term survival of NHL patients, we investigated whether the absorbed dose (AD) to the artery wall in radioimmunotherapy of NHL is of potential concern for delayed toxicity. SPECT resolution is not sufficient to enable dosimetric analysis of anatomic features of the thickness of the aortic wall. Therefore, we present a model of aortic wall toxicity based on data from 4 patients treated with 131I- tositumomab. Methods: Four NHL patients with periaortic tumors were administered pretherapeutic 131I-tositumomab. Abdominal SPECT and whole-body planar images were obtained at 48, 72, and 144 h after tracer administration. Blood-pool activity concentrations were obtained from regions of interest drawn on the heart on the planar images. Tumor and blood activity concentrations, scaled to therapeutic administered activities - both standard and myeloablative - were input into a geometry and tracking model (GEANT, version 4) of the aorta. The simulated energy deposited in the arterial walls was collected and fitted, and the AD and biologic effective dose values to the aortic wall and tumors were obtained for standard therapeutic and hypothetical myeloablative administered activities. Results: Arterial wall ADs from standard therapy were lower (0.6-3.7 Gy) than those typical from external-beam therapy, as were the tumor ADs (1.4-10.5 Gy). The ratios of tumor AD to arterial wall AD were greater for radioimmunotherapy by a factor of 1.9-4.0. For myeloablative therapy, artery wall ADs were in general less than those typical for external-beam therapy (9.4-11.4 Gy for 3 of 4 patients) but comparable for 1 patient (32.6 Gy). Conclusion: Blood vessel radiation dose can be estimated using the software package 3D-RD combined with GEANT modeling. The dosimetry analysis suggested that arterial wall toxicity is highly unlikely in standard dose radioimmunotherapy but should be considered a potential concern and limiting factor in myeloablative therapy.

AB - Tumors in non-Hodgkin lymphoma (NHL) patients are often proximal to the major blood vessels in the abdomen or neck. In external-beam radiotherapy, these tumors present a challenge because imaging resolution prevents the beam from being targeted to the tumor lesion without also irradiating the artery wall. This problem has led to potentially life-threatening delayed toxicity. Because radioimmunotherapy has resulted in long-term survival of NHL patients, we investigated whether the absorbed dose (AD) to the artery wall in radioimmunotherapy of NHL is of potential concern for delayed toxicity. SPECT resolution is not sufficient to enable dosimetric analysis of anatomic features of the thickness of the aortic wall. Therefore, we present a model of aortic wall toxicity based on data from 4 patients treated with 131I- tositumomab. Methods: Four NHL patients with periaortic tumors were administered pretherapeutic 131I-tositumomab. Abdominal SPECT and whole-body planar images were obtained at 48, 72, and 144 h after tracer administration. Blood-pool activity concentrations were obtained from regions of interest drawn on the heart on the planar images. Tumor and blood activity concentrations, scaled to therapeutic administered activities - both standard and myeloablative - were input into a geometry and tracking model (GEANT, version 4) of the aorta. The simulated energy deposited in the arterial walls was collected and fitted, and the AD and biologic effective dose values to the aortic wall and tumors were obtained for standard therapeutic and hypothetical myeloablative administered activities. Results: Arterial wall ADs from standard therapy were lower (0.6-3.7 Gy) than those typical from external-beam therapy, as were the tumor ADs (1.4-10.5 Gy). The ratios of tumor AD to arterial wall AD were greater for radioimmunotherapy by a factor of 1.9-4.0. For myeloablative therapy, artery wall ADs were in general less than those typical for external-beam therapy (9.4-11.4 Gy for 3 of 4 patients) but comparable for 1 patient (32.6 Gy). Conclusion: Blood vessel radiation dose can be estimated using the software package 3D-RD combined with GEANT modeling. The dosimetry analysis suggested that arterial wall toxicity is highly unlikely in standard dose radioimmunotherapy but should be considered a potential concern and limiting factor in myeloablative therapy.

KW - Lymphoma

KW - Monte Carlo

KW - Oncology

KW - Radiobiology/dosimetry

KW - Radioimmunotherapy

KW - Radionuclide therapy

KW - SPECT/CT

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=77950365150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950365150&partnerID=8YFLogxK

U2 - 10.2967/jnumed.109.069575

DO - 10.2967/jnumed.109.069575

M3 - Article

C2 - 20150265

AN - SCOPUS:77950365150

VL - 51

SP - 368

EP - 375

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 3

ER -